You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer

Article metrics

Article menu

Download PDFPDF

XML
Immunotherapy biomarkers
Original research
Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: April 2020 to March 2024

AbstractFullPdf
Apr 202010810839
May 2020294294148
Jun 202020620613
Jul 202045458
Aug 2020282611
Sep 2020606043
Oct 2020393915
Nov 2020404019
Dec 2020333317
Jan 2021414116
Feb 2021575725
Mar 2021606022
Apr 2021606022
May 2021252516
Jun 2021292913
Jul 202120208
Aug 2021353520
Sep 2021434326
Oct 2021353528
Nov 2021373629
Dec 2021262713
Jan 2022272812
Feb 2022232515
Mar 2022323516
Apr 2022333542
May 2022333322
Jun 2022303011
Jul 2022394120
Aug 2022303123
Sep 2022484817
Oct 2022404124
Nov 2022272930
Dec 2022212110
Jan 202324249
Feb 2023636324
Mar 2023363718
Apr 202316168
May 202323249
Jun 202323269
Jul 202312128
Aug 2023222212
Sep 2023202011
Oct 2023333314
Nov 2023242415
Dec 202326268
Jan 2024293019
Feb 2024222219
Mar 2024222243
Total209921171019